Electra Therapeutics (ETRA) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sagimet Biosciences Series A is the larger company by market cap ($623.3 million vs $563.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETRA | SGMT |
|---|---|---|
| Share price | $8.97 | $8.79 |
| Market cap | $563.02M | $623.29M |
| 1-day change | -2.07% | -1.01% |
| YTD return | — | +50.00% |
| 1-year return | — | +20.98% |
| EPS (TTM) | $-2.65 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.50 | $11.45 |
| 52-week low | $8.86 | $4.50 |
| Distance from 52-week high | -42.13% | -23.22% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +217.52% |
| Average volume | 948.89K | 1.23M |
| Shares outstanding | 62.77M | 70.34M |
| Employees | 46 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
ETRA vs SGMT FAQ
Which is bigger, Electra Therapeutics or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $623.29M compared with $563.02M for Electra Therapeutics (ETRA).
Are Electra Therapeutics and Sagimet Biosciences Series A in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Electra Therapeutics and Biotechnology: Pharmaceutical Preparations for Sagimet Biosciences Series A.